Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap59.19M
Enterprise Value33.39M
ALGS
(NASDAQ)Aligos Therapeutics, Inc.
$5.65-- (--)
Loading... - Market loading
Aligos Therapeutics (ALGS) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)12.58
Forward Price/Sales8.74
Price/Book (mrq)1.86
Price/Tangible Book (mrq)1.86
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue7.10
EV/Earnings-0.37
EV/EBITDA-0.39
EV/EBIT-0.38
EV/FCF-0.39
Stock Price
Current price, 52-week range, and moving averages
Current Price$5.69
1-Day Change7.77%
52-Week High$13.69
52-Week Low$4.80
52-Week Change-24.64%
YTD Change-37.68%
1-Year Change-20.75%
50-Day MA$6.04
200-Day MA$8.04
Avg Volume (30 day)120.74K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding10.40M
Book Value per Share$3.06
Net Cash per Share$2.48
FCF per Share$-8.19
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$72.50
Target Upside/Downside1174.17%
Analyst ConsensusBuy
Analyst Count4
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin89.03%
EBITDA Margin (ttm)-1817.87%
EBIT Margin (ttm)-1870.03%
Operating Margin (ttm)-2033.39%
Pretax Margin (ttm)-1907.18%
Profit Margin (ttm)-1919.68%
FCF Margin (ttm)-1810.52%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-284.13%
Return on Assets (ttm)-139.91%
Return on Invested Capital (ttm)-1160.79%
Return on Capital Employed (ttm)-213.37%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue4.71M
Gross Profit4.19M
Operating Income-95.67M
Pretax Income-89.73M
Net Income-90.32M
EBITDA-85.53M
EBIT-87.98M
Diluted EPS$-8.70
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-84.72M
Capital Expenditures463.00K
Free Cash Flow-85.19M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth43.88%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)64.56M
Cash & Securities (mrq)30.15M
Net Cash (mrq)25.80M
Net Cash per Share$2.48
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)4.35M
Working Capital (mrq)36.31M
Total Equity (mrq)31.79M
Book Value per Share$3.06
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)2.56
Quick Ratio (mrq)2.56
Debt/Equity (mrq)0.14
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-152.59%
FCF Yield-143.91%
Buyback Yield-0.21%
Total Shareholder Yield-0.21%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-38.04
Piotroski F-Score3/9
Frequently Asked Questions About Aligos Therapeutics Statistics
What are the key financial metrics for ALGS?
Aligos Therapeutics, Inc. (ALGS) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is ALGS's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Aligos Therapeutics is overvalued or undervalued.
How do I read ALGS's profitability ratios?
Aligos Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do ALGS's debt ratios indicate?
The financial health section shows Aligos Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is ALGS's dividend analysis?
The dividend section covers Aligos Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.